Via Merck KGaA Deal, GSK adds to growing immuno-oncology pipeline

Two months after announcing it would pay $5.1 billion for Tesaro Inc., GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has partnered with Merck KGaA (Xetra:MRK) in another deal to bolster its immuno-oncology pipeline.

GSK is paying the German

Read the full 349 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE